Fumarate d'EPT (N-éthyl-N-propyltryptamine)

EPT Fumarate (N-ethyl-N-propyltryptamine) – Scientific Product Description

General Features

EPT Fumarate is a research chemical from the tryptamine class, characterized by its unique N-ethyl-N-propyl substitution pattern. This compound exhibits structural similarities to known tryptamines such as DMT and MET, but is distinguished by specific pharmacodynamic properties.

Core specifications:

• Chemical Purity:  >98% (verified by HPLC-MS)

• Molecular Stability:  Excellent stability due to fumarate salt formation

• Solubilité:  Freely soluble in water and organic solvents

• Conditions de stockage :  Long-term stability at -20°C in inert gas atmosphere

Applications scientifiques

1. Recherche neuropharmacologique :

   • Serotonergic Receptor Interactions (5-HT1A/2A/2C)

   • Monoamine oxidase inhibition studies

   • Neurotransmitter release mechanisms

2. Études métaboliques :

   • Liver microsome metabolism profile

   • Cytochrome P450 interaction analysis

3. Pharmacologie comparée :

   • Structure-activity relationships versus other N,N-dialkyltryptamines

   • Dose-response characterization in vitro

Directives expérimentales

Dosage Ranges for In Vitro Studies:

Safety protocols:

• Always work under controlled laboratory conditions

• Personal protective equipment (lab coat, nitrile gloves, safety glasses) required

• Use only in a fume hood when handling solvents

Données de stabilité

Documented Stability:

• Room temperature: <72 hours in solution

• Refrigerated (4°C): stable for 1 week

• Frozen (-20°C): stable for >6 months

Stockage recommandé :

• Primary packaging: Amber glass vials with PTFE closure

• Secondary packaging: Vacuum sealed with silica gel pack

• Storage conditions: -20°C under argon atmosphere

Certification analytique

Chaque lot est livré avec :

1. Extensive HPLC analysis (UV/VIS detection)

2. Mass spectrometry confirmation (LC-MS/MS)

3. Analyse des solvants résiduels

4. Water content determination (Karl Fischer)

Legal Status & Ethics

Dutch Regulations:

• Currently not included in the Opium Act

• Valid under general medicinal products legislation for research chemicals

• Mandatory registration for scientific institutions

Lignes directrices éthiques :

• For non-clinical research use only

• Prohibited for human or animal administration

• Mandatory ethical review for academic research

Questions fréquemment posées

Q1: How does EPT compare to structurally similar tryptamines?
A: The ethyl-propyl substitution exhibits unique pharmacokinetic properties, particularly in:

• Lipophilicity profile (logP value: 2.1)

• Protein binding capacity (88-92%)

• Brain barrier penetration (0.65 ratio to DMT)

Q2: What are the detection options in standard drug screenings?
A: EPT is not recognized by conventional immunoassays, but is detectable via:

• GC-MS (characteristic fragmentation at m/z 130, 144)

• LC-QTOF (precision measurement of molecular mass)

Q3: Are there any known interactions with medications?
A: Theoretical interactions are possible with:

• MAO inhibitors (potentiation effect)

• SSRIs (competitive inhibition)

• Antipsychotics (receptor competition)

Q4: What is the recommended waste disposal?
A: Follow the hazardous waste protocol:

• Neutralize with dilute hydrochloric acid (0.1M)

• Absorb with suitable material (e.g. vermiculite)

• Dispose of as hazardous chemical waste (EC number: 404-860-3)

Références scientifiques

Important literature references:

1. Nichols, D. E. (2018). “Structure-activity relationships of tryptamines”

2. Brandt et al. (2020). « Caractérisation analytique de nouvelles substances psychoactives »

3. Système d'alerte précoce de l'UE (2023). « Évaluation des risques liés aux nouveaux dérivés de la tryptamine »

This product is intended solely for authorized scientific research by qualified personnel. All information is provided without any implied warranty. Users are responsible for complying with local regulations.